RNA interference has quietly become the most commercially proven RNA modality in biotech — Alnylam now runs a profitable, multi-billion-dollar business on six approved drugs, turning what was once Nobel-Prize-winning science into a genuine pharmaceutical powerhouse.
📈 What changed: Alnylam crossed $1B in quarterly product revenues for the first time in Q1 2026, one year after AMVUTTRA's U.S. launch for ATTR-CM.
| Indicator | Score | Reading |
|---|---|---|
| Maturity higher is better · high confidence | 85/100 | The most commercially mature RNA modality in this batch: six FDA-approved RNAi drugs and a pioneer that just crossed $1B in quarterly product revenue. |
| Evidence Strength higher is better · high confidence | 75/100 | Audited SEC filings from the clear market leader anchor the strongest claims; independent market-research houses converge on continued double-digit growth. |
| Commercial Proximity higher is better · high confidence | 85/100 | The clearest proven commercial wedge in the entire cell-and-gene-therapy-adjacent cluster, with the market leader now profitable. |
| Capital & Policy Support higher is better · medium confidence | 36/100 | No dedicated multi-year public funding programme; growth is driven by reimbursed product sales and biopharma royalty partnerships rather than public spend. |
| Crowding Risk lower is better · medium confidence | 57/100 | A single dominant, now-profitable company anchors the theme; positioning reflects a maturing growth story rather than speculative crowding. |
| Reflexivity Risk lower is better · medium confidence | 19/100 | The most earnings-grounded name in this cluster: a profitable, multi-billion-dollar revenue business rather than a binary-catalyst clinical-stage story. |
Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.
The public page is the summary (backed by 8 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.
Open in the appStart free →The Northstar Signal — what moved across all 350 themes and why, in your inbox. Free, no spam, one-click unsubscribe.